Abstract
Immunex, a small Seattle biotechnology company, stumbles into a hugely successful and groundbreaking product. Enbrel, a tumor necrosis factor, is immediately recognized as the most effective treatment for rheumatoid arthritis–a $300 billion market in the United States. After almost 20 years of unprofitability, Enbrel is a lifesaver for Immunex. But it could also become the company's worst nightmare. Immunex, after years of being cash starved, has not been able to build production capabilities to satisfy the sudden and massive demand for its drug.To illustrate the decision-making process concerning how and when to build commercialization capabilities in a small biotechnology company. Also, to explore options for reacting to an unexpected demand in a hypercompetitive market.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
